Celgene in $450m deal to commercialise MedImmune's anti-PD-L1 candidate
AstraZeneca has inked a development and commercialisation deal with Celgene for its haematology programmed cell death ligand 1 (PD-L1) candidate, MEDI4736.
Archives for April 27, 2015
News from CPhI Japan
Sakigake: New Japanese drug laws will foster global innovation says MHLW
‘Epoch making’ revisions to Japanese drug laws have provided a pathway for development of safer, more innovative drugs according to MHLW director, Haruo Akagawa.
Lilly to sell California biomanufacturing plant
Eli Lilly has hired CBRE Group to sell its biomanufacturing plant in Vacaville, California, which it claims is one of the largest bulk API manufacturing facilities for recombinant microbial-based biopharmaceuticals in the US.